Literature DB >> 22731491

USP18 establishes the transcriptional and anti-proliferative interferon α/β differential.

Véronique Francois-Newton1, Mark Livingstone, Béatrice Payelle-Brogard, Gilles Uzé, Sandra Pellegrini.   

Abstract

Type I IFNs (interferons) are pathogen-induced immunoregulatory cytokines that exert anti-viral and anti-proliferative activities through binding to a common cell-surface receptor. Among the 17 human IFN subtypes, IFNβ binds the IFNAR (IFNα receptor) 1/IFNAR2 receptor chains with particularly high affinity and is especially potent in select bioactivities (e.g. anti-proliferative and pro-apoptotic) when compared with IFNα2. However, no molecular basis has been ascribed to this differential action, since the two ligands are equipotent in immediate early signalling events. In the present study we report that IFNβ induces Stat (signal transducer and activator of transcription) phosphorylation and transcriptional activation of ISGs (interferon-stimulated genes), including two genes with pro-apoptotic functions, for a considerably longer time frame than does IFNα2. We show that the diversification of α2/β responses progressively builds up at the receptor level as a result of accumulating USP18 (ubiquitin specific protease 18), itself an ISG, which exerts its negative feedback action by taking advantage of the weakness of IFNα2 binding to the receptor. This represents a novel type of signalling regulation that diversifies the biological potential of IFNs α and β.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22731491     DOI: 10.1042/BJ20120541

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  34 in total

1.  Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses.

Authors:  Stephan Wilmes; Polly-Anne Jeffrey; Jonathan Martinez-Fabregas; Maximillian Hafer; Paul K Fyfe; Elizabeth Pohler; Silvia Gaggero; Martín López-García; Grant Lythe; Charles Taylor; Thomas Guerrier; David Launay; Suman Mitra; Jacob Piehler; Carmen Molina-París; Ignacio Moraga
Journal:  Elife       Date:  2021-04-19       Impact factor: 8.140

Review 2.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

3.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

4.  Developing Broad-Spectrum Antivirals Using Porcine and Rhesus Macaque Models.

Authors:  Xueer Qiu; Justin Taft; Dusan Bogunovic
Journal:  J Infect Dis       Date:  2020-03-02       Impact factor: 5.226

Review 5.  Targeting of type I interferon in systemic autoimmune diseases.

Authors:  Mary K Crow; Mikhail Olferiev; Kyriakos A Kirou
Journal:  Transl Res       Date:  2014-10-16       Impact factor: 7.012

6.  Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness.

Authors:  Pil Soo Sung; HyeonJoo Cheon; Chung Hwan Cho; Seon-Hui Hong; Do Youn Park; Hyung-Il Seo; Su-Hyung Park; Seung Kew Yoon; George R Stark; Eui-Cheol Shin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

7.  Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression.

Authors:  Christopher R Bolen; Siyuan Ding; Michael D Robek; Steven H Kleinstein
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

8.  JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency.

Authors:  Fahad Alsohime; Marta Martin-Fernandez; Mohamad-Hani Temsah; Majed Alabdulhafid; Tom Le Voyer; Malak Alghamdi; Xueer Qiu; Najla Alotaibi; Areej Alkahtani; Sofija Buta; Emmanuelle Jouanguy; Ayman Al-Eyadhy; Conor Gruber; Gamal M Hasan; Fahad A Bashiri; Rabih Halwani; Hamdy H Hassan; Saleh Al-Muhsen; Nouf Alkhamis; Zobaida Alsum; Jean-Laurent Casanova; Jacinta Bustamante; Dusan Bogunovic; Abdullah A Alangari
Journal:  N Engl J Med       Date:  2020-01-16       Impact factor: 91.245

9.  Antiviral activity of bone morphogenetic proteins and activins.

Authors:  Lucy A Eddowes; Kinda Al-Hourani; Narayan Ramamurthy; Jamie Frankish; Hannah T Baddock; Cynthia Sandor; John D Ryan; Dahlene N Fusco; João Arezes; Eleni Giannoulatou; Sara Boninsegna; Stephane Chevaliez; Benjamin M J Owens; Chia Chi Sun; Paolo Fabris; Maria Teresa Giordani; Diego Martines; Slobodan Vukicevic; John Crowe; Herbert Y Lin; Jan Rehwinkel; Peter J McHugh; Marco Binder; Jodie L Babitt; Raymond T Chung; Matthew W Lawless; Andrew E Armitage; Caleb Webber; Paul Klenerman; Hal Drakesmith
Journal:  Nat Microbiol       Date:  2018-12-03       Impact factor: 17.745

10.  Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation.

Authors:  Xianqin Zhang; Dusan Bogunovic; Béatrice Payelle-Brogard; Véronique Francois-Newton; Scott D Speer; Chao Yuan; Stefano Volpi; Zhi Li; Ozden Sanal; Davood Mansouri; Ilhan Tezcan; Gillian I Rice; Chunyuan Chen; Nahal Mansouri; Seyed Alireza Mahdaviani; Yuval Itan; Bertrand Boisson; Satoshi Okada; Lu Zeng; Xing Wang; Hui Jiang; Wenqiang Liu; Tiantian Han; Delin Liu; Tao Ma; Bo Wang; Mugen Liu; Jing-Yu Liu; Qing K Wang; Dilek Yalnizoglu; Lilliana Radoshevich; Gilles Uzé; Philippe Gros; Flore Rozenberg; Shen-Ying Zhang; Emmanuelle Jouanguy; Jacinta Bustamante; Adolfo García-Sastre; Laurent Abel; Pierre Lebon; Luigi D Notarangelo; Yanick J Crow; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Sandra Pellegrini
Journal:  Nature       Date:  2014-10-12       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.